PBO PH20 SC

DRUG2 trials

Sponsors

Argenx

Conditions

Bullous PemphigoidBullous Pemphigoid (BP)

Phase 2

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

CompletedCTIS2023-508645-40-00

ArgenxBullous Pemphigoid (BP)

Start: 2022-05-10End: 2024-09-13Target: 90Updated: 2024-08-22

Phase 3

An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

CompletedCTIS2024-515832-59-00

ArgenxBullous Pemphigoid

Start: 2022-05-03End: 2025-01-13Target: 43Updated: 2025-01-23